🔎 Trials Near Me

Home › Diffuse Large B-Cell Lymphoma › Maryland

Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Maryland

13 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Maryland.

Mga Lungsod sa Maryland

Opisyal na teksto ng pag-aaral (English)

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
  • The Center for Cancer and Blood Disorders, Bethesda
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06500273

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  • Walter Reed National Military Medical Center, Bethesda
  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06649812

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • American Oncology Partners of Maryland Pa, Bethesda
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT03223610

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  • American Oncology Partners, P.A. ( Site 0185), Bethesda
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06717347

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  • University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06091865

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04002947

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05389423

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

  • University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT06116110

DALY II USA/ MB-CART2019.1 for DLBCL

  • University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • National Institute of Health, Bethesda
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • National Institutes of Health Clinical Center, Bethesda
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT04830137

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 2, 2026 · NCT05633615

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.